FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1986782870> ?p ?o ?g. }

• W1986782870 endingPage "2423" @default.
• W1986782870 startingPage "2410" @default.
• W1986782870 abstract "Abstract Purpose: Small molecule inhibitors of the mitogen-activated protein kinase (MAPK) pathway, such as sorafenib, represent novel treatment options for advanced hepatocellular carcinoma. The aim of our study was to identify downstream targets as biomarker candidates that are directly linked to the oncogenic MAPK pathway in hepatocellular carcinoma and correlate with inhibition of this pathway by multikinase inhibitors. Experimental Design: Hepatocellular carcinoma cell lines and fresh tumor and tumor-free liver tissues from patients with hepatocellular carcinoma were incubated with different BRaf or MEK inhibitors and analyzed for kinase phosphorylation, proliferation, induction of apoptosis, and chemokine secretion. Results: Hepatocellular carcinoma cell lines responded differentially to these inhibitors in a dose-dependent manner, even those targeting the same kinase. Sorafenib inhibited both MEK1 and ERK1/2 phosphorylation at high but increased signaling at low concentrations. Similarly, PLX4720 increased MEK/ERK signaling independently from mutations in BRaf or NRas. MEK inhibitors decreased ERK1/2 phosphorylation in a dose-dependent manner. These signaling characteristics correlated with inhibition of proliferation, induction of apoptosis, and chemokine secretion. Fresh tissues derived from patients diagnosed with primary hepatocellular carcinoma responded to these inhibitors with changes in their microenvironment following the patterns observed in hepatocellular carcinoma cells. Conclusions: Oncogenic signaling of the MAPK pathway influences hepatocellular carcinoma sensitivity to treatment with BRaf and MEK inhibitors about cell fate independently from mutations in BRaf and NRas. MAPK inhibitors have a strong impact on chemokine secretion as a consequence of interference with oncogenic signaling. Therefore, novel biomarker candidates associated with the hepatocellular carcinoma microenvironment may be developed for prediction and monitoring of treatment response to small molecule inhibitors. Clin Cancer Res; 20(9); 2410–23. ©2014 AACR." @default.
• W1986782870 created "2016-06-24" @default.
• W1986782870 creator A5002183557 @default.
• W1986782870 creator A5004040780 @default.
• W1986782870 creator A5004518271 @default.
• W1986782870 creator A5012176987 @default.
• W1986782870 creator A5017751654 @default.
• W1986782870 creator A5021318126 @default.
• W1986782870 creator A5032232252 @default.
• W1986782870 creator A5048928370 @default.
• W1986782870 creator A5066232501 @default.
• W1986782870 date "2014-04-30" @default.
• W1986782870 modified "2023-09-26" @default.
• W1986782870 title "BRaf and MEK Inhibitors Differentially Regulate Cell Fate and Microenvironment in Human Hepatocellular Carcinoma" @default.
• W1986782870 cites W1587290807 @default.
• W1986782870 cites W1963713713 @default.
• W1986782870 cites W1963920328 @default.
• W1986782870 cites W1965397916 @default.
• W1986782870 cites W1967554392 @default.
• W1986782870 cites W1971087422 @default.
• W1986782870 cites W1974091059 @default.
• W1986782870 cites W1983357242 @default.
• W1986782870 cites W1989145928 @default.
• W1986782870 cites W1995065358 @default.
• W1986782870 cites W2001531382 @default.
• W1986782870 cites W2004295816 @default.
• W1986782870 cites W2016940195 @default.
• W1986782870 cites W2018786027 @default.
• W1986782870 cites W2025630491 @default.
• W1986782870 cites W2038625523 @default.
• W1986782870 cites W2042045861 @default.
• W1986782870 cites W2043058822 @default.
• W1986782870 cites W2053593582 @default.
• W1986782870 cites W2054730738 @default.
• W1986782870 cites W2058887247 @default.
• W1986782870 cites W2061746936 @default.
• W1986782870 cites W2063488708 @default.
• W1986782870 cites W2070396671 @default.
• W1986782870 cites W2076093607 @default.
• W1986782870 cites W2080527870 @default.
• W1986782870 cites W2087251851 @default.
• W1986782870 cites W2088611209 @default.
• W1986782870 cites W2094475660 @default.
• W1986782870 cites W2095243258 @default.
• W1986782870 cites W2101624426 @default.
• W1986782870 cites W2102942095 @default.
• W1986782870 cites W2122419529 @default.
• W1986782870 cites W2123096563 @default.
• W1986782870 cites W2127107746 @default.
• W1986782870 cites W2129245282 @default.
• W1986782870 cites W2132711541 @default.
• W1986782870 cites W2136745780 @default.
• W1986782870 cites W2139213909 @default.
• W1986782870 cites W2140657586 @default.
• W1986782870 cites W2144051767 @default.
• W1986782870 cites W2144169031 @default.
• W1986782870 cites W2147673725 @default.
• W1986782870 cites W2149662085 @default.
• W1986782870 cites W2153819918 @default.
• W1986782870 cites W2154196978 @default.
• W1986782870 cites W2156871508 @default.
• W1986782870 cites W2163614144 @default.
• W1986782870 cites W2165073006 @default.
• W1986782870 cites W2166310425 @default.
• W1986782870 cites W2183125843 @default.
• W1986782870 cites W4243625103 @default.
• W1986782870 doi "https://doi.org/10.1158/1078-0432.ccr-13-1635" @default.
• W1986782870 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24573550" @default.
• W1986782870 hasPublicationYear "2014" @default.
• W1986782870 type Work @default.
• W1986782870 sameAs 1986782870 @default.
• W1986782870 citedByCount "16" @default.
• W1986782870 countsByYear W19867828702014 @default.
• W1986782870 countsByYear W19867828702015 @default.
• W1986782870 countsByYear W19867828702016 @default.
• W1986782870 countsByYear W19867828702017 @default.
• W1986782870 countsByYear W19867828702018 @default.
• W1986782870 countsByYear W19867828702019 @default.
• W1986782870 countsByYear W19867828702020 @default.
• W1986782870 crossrefType "journal-article" @default.
• W1986782870 hasAuthorship W1986782870A5002183557 @default.
• W1986782870 hasAuthorship W1986782870A5004040780 @default.
• W1986782870 hasAuthorship W1986782870A5004518271 @default.
• W1986782870 hasAuthorship W1986782870A5012176987 @default.
• W1986782870 hasAuthorship W1986782870A5017751654 @default.
• W1986782870 hasAuthorship W1986782870A5021318126 @default.
• W1986782870 hasAuthorship W1986782870A5032232252 @default.
• W1986782870 hasAuthorship W1986782870A5048928370 @default.
• W1986782870 hasAuthorship W1986782870A5066232501 @default.
• W1986782870 hasBestOaLocation W19867828702 @default.
• W1986782870 hasConcept C11960822 @default.
• W1986782870 hasConcept C121608353 @default.
• W1986782870 hasConcept C126322002 @default.
• W1986782870 hasConcept C184235292 @default.
• W1986782870 hasConcept C190283241 @default.
• W1986782870 hasConcept C21790070 @default.
• W1986782870 hasConcept C2776107976 @default.
• W1986782870 hasConcept C2778019345 @default.

• next